[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: They will take routine treatment approved by the Ministry of Health for patients with adult respiratory distress from COVID 19,Also the subcutaneous injection of Enaxaparin one mg per kilogram of body weight for the patient added to their treatment .", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: 15 cases : A-Alteplase (TPA) 25-50 mg ( half of the maximum dose 0.9 / kg /day) over 2 hours intravenous continuing by 25-50 /22 hours up to maximum dose of 0.9 mg/kg/d. This tPA injection may be repeated for 2 days and the patient's condition (PT level PTT, SPO2 and D- dimer) is observed and checked. After the end of TPA injection, subcutaneous injection of Enoxaparin will be started as 1 mg per kilogram body weight for the patient. Enoxaparin could be continued up to 7 days upon the condition of the patient. The patients will receive regular care and treatment for COVID-19 induced ARDS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 463, "treatment_name": "Enoxaparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1406, "treatment_name": "Alteplase+enoxaparin", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}]